In This Article:
Annual General Meeting of Kuros Biosciences approves all resolutions
Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today.
The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2024 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the Executive Committee, voted in favor of the proposed appropriation of the Annual Results, and approved compensation for the members of the Board of Directors and the Executive Committee. Clemens van Blitterswijk was re-elected as Chairman and Joost de Bruijn, Oliver Walker, Albert Arp and Chris Fair (CEO) were re-elected as members of the Board. Kimberley Elting was elected as a new member of the Board of Directors. Clemens van Blitterswijk, Oliver Walker and Albert Arp were re-elected as members of the Compensation Committee.
The law firm Keller AG, Zurich, was re-elected as independent Proxy. PricewaterhouseCoopers Ltd, Basel, were re-elected for another one-year term as Kuros' auditor. The Annual General Meeting also approved the U.S. Option and Equity Incentive Plan Regulation 2025.
The Annual General Meeting further approved, with the required 2/3 majority, adjustments to the Articles of Association to increase the Conditional Share Capital for Employees, Persons of Comparable Positions and Board Members.
The Annual General Meeting took place at JED Events, Zürcherstrasse 39E, 8952 Schlieren (Zurich). 19,610,174 shares or 51.8% of a total of 37,868,889 shares were represented.
For further information, please contact:
Alexandre Müller | Daniel Geiger |
Investor Relations | Chief Financial Officer |
Tel +41 43 268 32 31 | Tel +41 44 733 47 41 |
About MagnetOs
MagnetOsTM is a bone graft like no other: thanks to its NeedleGripTM surface technology, it grows bone even in soft tissues. This surface technology provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages). This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft. The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion. *†‡1-5
Indications Statement
Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions.